Fundraising Fox
/Companies
Sign in

Intershunt

Fridley, US · Founded 2015 · 11 employees on LinkedIn · 1 known investors

Find your way into Intershunt

Sign up to see every warm intro you have to Intershunt

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Intershunt team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Intershunt develops the Dynama System (also known as the PAS-C System), an investigational interatrial shunting device designed to create a pathway in the heart's upper chambers to reduce elevated left atrial pressure and relieve heart failure symptoms. It targets select heart failure patients with reduced ejection fraction and is being evaluated in the EASE HF2 early feasibility clinical study.

HardwareHealthtechMedical Devices

Founders & leadership

HL
Harlan Lee SorkinExecutive
GM
Gil M. VardiNamed on SEC filing

Board

DHDenis Harrington
Denis HarringtonChair Of The Board Of Directors2021–2025Executive Officer, Director at VentureMed Group
DADavid Adair
David AdairMember Board Of DirectorsCo-Founder and Managing Director at Solas BioVentures
JB
Jim BullockBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$27.4M disclosed across 3 rounds · 2020–2024

▶$23.4MraisedSep 2024 · 35 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Denis HarringtonDirector
  • Gil M. VardiDirector
  • David AdairDirector
  • Jim BullockDirector
  • Harlan Lee SorkinExecutive Officer, Director
Offering amount
$30.4M
Amount sold
$23.4M
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$885.7KraisedDec 2021 · 13 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • James BullockDirector
  • Denis HarringtonDirector
  • Gil M. VardiDirector
  • Harlan L. SorkinExecutive Officer, Director
  • David AdairDirector
Offering amount
$3.5M
Amount sold
$885.7K
First sale
Dec 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.1MraisedJan 2021 · 28 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Gil M. VardiDirector
  • Harian Lee SorkinExecutive Officer, Director
Offering amount
$3.6M
Amount sold
$3.1M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

Rf SurgicalMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
VumediVumedi operates a peer-to-peer video education platform where clinicians watch lectures and technique videos across dozens of medical specialties. It partners with academic institutions, hospitals, and life sciences companies to provide continuing medical education content to doctors.
Corvia MedicalDeveloper of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.

Companies working in the same space as Intershunt.

Frequently asked questions

What does Intershunt do?
Intershunt develops the Dynama System (also known as the PAS-C System), an investigational interatrial shunting device designed to create a pathway in the heart's upper chambers to reduce elevated left atrial pressure and relieve heart failure symptoms. It targets select heart failure patients with reduced ejection fraction and is being evaluated in the EASE HF2 early feasibility clinical study.
Who are Intershunt's investors?
Intershunt's investors include Solas BioVentures.
How much funding has Intershunt raised?
Intershunt has disclosed $27.4M raised across 3 rounds.
Where is Intershunt headquartered?
Intershunt is headquartered in Fridley, US.